Nature Communications (Mar 2022)

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

  • Julia Joung,
  • Paul C. Kirchgatterer,
  • Ankita Singh,
  • Jang H. Cho,
  • Suchita P. Nety,
  • Rebecca C. Larson,
  • Rhiannon K. Macrae,
  • Rebecca Deasy,
  • Yuen-Yi Tseng,
  • Marcela V. Maus,
  • Feng Zhang

DOI
https://doi.org/10.1038/s41467-022-29205-8
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 14

Abstract

Read online

Loss-of-function CRISPR-based screens have identified several genes associated with cancer resistance to T cell-induced cytotoxicity. Here the authors perform a genome-scale, gain-of-function CRISPR screen and identify candidate genes, including the poly-N-acetyllactosamine synthase B3GNT2, whose overexpression confers tumor cell resistance to T cell cytotoxicity